Status:
COMPLETED
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma
Lead Sponsor:
Cell Genesys
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell...
Eligibility Criteria
Inclusion
- De novo multiple myeloma
- ECOG 0-2
- No serious co-morbid illnesses and adequate organ function
- \> 4 weeks from systemic steroids
Exclusion
- No existing secondary malignancies and no history of secondary malignancies in the past 5 years
- No active autoimmune disease
Key Trial Info
Start Date :
October 1 2000
Trial Type :
INTERVENTIONAL
End Date :
October 1 2004
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00116441
Start Date
October 1 2000
End Date
October 1 2004
Last Update
December 24 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21231